Business
Significant shareholder
Significant shareholder.
About this update from Hvivo Plc
[{"type":"text","content":"\n \nRNS Number : 3915C Open Orphan PLC 07 February 2020 \n\n7 February 2020\n \nOpen Orphan plc\n \n(\"Open Orphan\" or the \"Company\")\n \nSignificant shareholder\n \n \nOpen Orphan, the rapidly growing specialist CRO pharmaceutical services company which has a focus on orphan drugs and is a world leader in the provision of virology and vaccine challenge study services, has been advised today that, as of 31 January 2020, Jupiter Asset Management Limited's (\"Jupiter\") interest in the Ordinary Shares of 0.1p in the Company fell below 3% of the total voting rights of the Company. Accordingly, Jupiter have ceased to be a significant shareholder in the Company, as defined by the AIM Rules for Companies.\n \n \nFor further information please contact:\n \n\n\n\nOpen Orphan plc\nCathal Friel, Executive Chairman \nTrevor Phillips, Chief Executive Officer\n\n\n \n+353 (0)1 644 0007\n+44 (0)20 7347 5350\n\n\n\n\n \n\n\n\n\n\n\n\nArden Partners plc (Nominated Adviser and Joint Broker)\nJohn Llewellyn-Lloyd / Benjamin Cryer\n\n\n+44 (0)20 7614 5900\n\n\n\n\n \n\n\n \n\n\n\n\n \n\n\n\n\n\n\n\nDavy (Euronext Growth Adviser and Joint Broker)\nAnthony Farrell\n\n\n+353 (0)1 679 6363\n\n\n\n\n \n\n\n \n\n\n\n\n \n\n\n\n\n\n\n\nCamarco (Financial PR)\n\n\n \n\n\n\n\nTom Huddart / Daniel Sherwen\n\n\n+44 (0)20 3757 4980\n\n\n\n \nNotes to Editors:\nOpen Orphan is a rapidly growing European full pharmaceutical services company with a focus on orphan drug and specialist services, comprising two commercial specialist CRO services businesses (Venn and hVIVO) and a developing early stage orphan drug genomics data platform business capturing valuable genetic data from patient populations with specific diseases with designated orphan drug status and incorporating AI tools. In June 2019, Open Orphan acquired AIM-listed Venn Life Sciences Holdings plc in a reverse take-over and in January 2020 it completed the Merger with hVIVO plc. Venn, as an integrated drug development consultancy, offers CMC (chemistry, manufacturing and controls) , preclinical, phase I & II clinical trials design and execution. hVIVO, is a world leader in the provi...